Update on adolescent immunization: Pertussis, meningococcus, HPV, and the future
Sylvia H. Yeh, MD
Assistant Professor of Pediatrics, University of California, Los Angeles; Department of Pediatric Infectious Disease, Harbor-UCLA Medical Center; Los Angeles Biomedical Research Institute, Torrance, CA
Jay M. Lieberman, MD
Professor of Pediatrics, University of California, Irvine; Department of Pediatric Infectious Diseases, Miller Children’s Hospital, Long Beach, CA
Address: Sylvia H. Yeh, MD, Harbor-UCLA Medical Center, UCLA Center for Vaccine Research, 1124 West Carson Street, Liu Research Building, Torrance, CA 90502; e-mail: firstname.lastname@example.org
Dr. Lieberman serves on the speakers’ bureaus of or as a consultant for the sanofi pasteur, GlaxoSmithKline, and Merck corporations.
ABSTRACTSince January 2005, new vaccines against pertussis, meningococcal disease, and human papillomavirus (HPV) infection have been licensed. The target recipients are adolescents and preadolescents, who are at higher risk of these infections than other age groups. Routinely scheduled visits for 11- to 12-year-olds will allow for immunization against these and other diseases and give us an opportunity to provide anticipatory guidance against high-risk behaviors.